Philogen Ties Up With Actinium To Develop Cancer-Targeted Radioisotope-Labeled Antibodies
This article was originally published in The Pink Sheet Daily
Executive Summary
Italy's Philogen is to evaluate alpha-particle emitting actinium as the cytotoxic payload for its angiogenesis-targeted monoclonal antibody platform, under a collaboration with New Jersey-based Actinium Pharmaceuticals.